Vicore Pharma Holding AB (OSTO:VICO) Notes Receivable: kr0.00 Mil (As of Mar. 2026)


OSTO:VICO Vicore Pharma Holding AB OSTO:VICO
30 GF Score
Price kr12.60
! 5 Warning Signs
View Full Analysis

What is Vicore Pharma Holding AB Notes Receivable?

Vicore Pharma Holding AB OSTO:VICO +2.94% 30 Notes Receivable is kr0.00 Mil as of Mar. 2026. GuruFocus rates OSTO:VICO with a GF Score™ of 30/100. The stock has 5 warning signs investors should review.

Vicore Pharma Holding AB's Notes Receivable for the quarter that ended in Mar. 2026 was kr0.00 Mil.

Vicore Pharma Holding AB Notes Receivable Related Terms

Vicore Pharma Holding AB Notes Receivable Historical Data

* Premium members only.

The historical data trend for Vicore Pharma Holding AB's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vicore Pharma Holding AB Notes Receivable Chart

Vicore Pharma Holding AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Vicore Pharma Holding AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OSTO:VICO
30GF Score
Vicore Pharma Holding AB OSTO:VICO
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vicore Pharma Holding AB Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of kr0.00 Mil mean?
Vicore Pharma Holding AB (OSTO:VICO) has a Notes Receivable of kr0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Vicore Pharma Holding AB and its competitors.
Is Vicore Pharma Holding AB's Notes Receivable too high?
Vicore Pharma Holding AB's current Notes Receivable is kr0.00 Mil. Overall, Vicore Pharma Holding AB has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Vicore Pharma Holding AB's Notes Receivable compare to VRTX and REGN?
Vicore Pharma Holding AB's Notes Receivable of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Vicore Pharma Holding AB and its competitors. Vicore Pharma Holding AB's current Notes Receivable is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vicore Pharma Holding AB stock overvalued right now?
Vicore Pharma Holding AB (OSTO:VICO) has a current Notes Receivable of kr0.00 Mil. The current Notes Receivable is kr0.00 Mil. Vicore Pharma Holding AB's overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Vicore Pharma Holding AB (OSTO:VICO), the current Notes Receivable is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vicore Pharma Holding AB Business Description

Other Exchanges 6Y4:Germany
Address Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
30GF Score

Get the complete analysis for OSTO:VICO

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr12.60
Price